Nightware receives breakthrough designation for its PTSD nightmare therapy technology

Oftentimes individuals suffering from post-traumatic stress disorder experience severe nightmares where they relive horrible experiences from their past over and over again. These kinds of nightmare disorders...

After Walmart, Mayo pushes further into workplace health

Rochester, Minnesota-based Mayo Clinic already has a Centers of Excellence program with Walmart, but through a new collaboration, it is making another move into the workplace health...

Alphabet’s Verily boosts its Project Baseline with new health system, pharma partners

Alphabet’s Verily life science division launched its Project Baseline back in 2017 with the ambition to make it easier for individuals to get involved in the...

Merck’s Keytruda fails in Phase III triple-negative breast cancer study, but has a few...

A clinical trial of Merck & Co.’s flagship oncology drug in a form of breast cancer has failed. However, the company is also running additional trials...

Nashville healthcare innovation fund Jumpstart Foundry adds 15 startups to its portfolio

Jumpstart Foundry, a Nashville, Tennessee-based seed stage healthcare innovation fund, has selected 15 startups for its 2019 cohort. The companies have footholds in the ambulatory, hospital,...

New antibiotics are urgently needed, but economics stand in the way

On March 10, 2017, shares of antibiotic developer Achaogen traded at $27 on the Nasdaq. Two years later, it has become a penny stock trading at around...

Cala Health raises $50M ahead of commercial launch of its bioelectric stimulation device

The Burlingame, California-based startup bills itself as a bioelectric medicine company that is using electric signals to stimulate the nervous system as a pathway to treat...

How one North Carolina managed care organization’s housing program has driven down crisis costs...

Payer organizations having been targeting social determinants of health as a way to drive lower healthcare spending and improve clinical outcomes. Housing – in particular –...

Amgen cancer drug targeting ‘undruggable’ mutation has potential as tumor-agnostic treatment

The biotech company plans to present Phase I data at ASCO on the drug, AMG 510, which targets KRAS mutations in solid tumors. Source link

In healthcare, which Avengers character are you?

A Walt Disney executive presents during CinemaCon at The Colosseum at Caesars Palace on April 03, 2019 in Las Vegas, Nevada. Photo by Gabe Ginsberg/WireImage What do...

Must Read